These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8368736)

  • 21. Immunotherapeutic strategies for cancer using poxvirus vectors.
    Paoletti E; Tartaglia J; Cox WI
    Ann N Y Acad Sci; 1993 Aug; 690():292-300. PubMed ID: 8368744
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
    Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
    Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
    J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.
    Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty LE; Richards JM; Bartolucci AA
    Cancer; 1995 Jan; 75(1):34-42. PubMed ID: 7804974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 26. Intratumoral immunotherapy for melanoma.
    Singh M; Overwijk WW
    Cancer Immunol Immunother; 2015 Jul; 64(7):911-21. PubMed ID: 26050024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on active specific immunotherapy with melanoma vaccines.
    Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
    J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.
    Estin CD; Stevenson US; Plowman GD; Hu SL; Sridhar P; Hellström I; Brown JP; Hellström KE
    Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1052-6. PubMed ID: 3422478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.
    Yee C; Gilbert MJ; Riddell SR; Brichard VG; Fefer A; Thompson JA; Boon T; Greenberg PD
    J Immunol; 1996 Nov; 157(9):4079-86. PubMed ID: 8892642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.
    Mukherji B; Guha A; Chakraborty NG; Sivanandham M; Nashed AL; Sporn JR; Ergin MT
    J Exp Med; 1989 Jun; 169(6):1961-76. PubMed ID: 2471770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational development of tumour antigen-specific immunization in melanoma.
    Gajewski TF; Fallarino F
    Ther Immunol; 1995 Aug; 2(4):211-25. PubMed ID: 9358613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
    Berthier-Vergnes O; Portoukalian J; Lefthériotis E; Doré JF
    Cancer Res; 1994 May; 54(9):2433-9. PubMed ID: 8162593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
    Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
    J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
    Smith CL; Dunbar PR; Mirza F; Palmowski MJ; Shepherd D; Gilbert SC; Coulie P; Schneider J; Hoffman E; Hawkins R; Harris AL; Cerundolo V
    Int J Cancer; 2005 Jan; 113(2):259-66. PubMed ID: 15386406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy using T cell defined tumor antigens for melanoma.
    Kawakami Y
    Microbiol Immunol; 1998; 42(12):801-13. PubMed ID: 10037214
    [No Abstract]   [Full Text] [Related]  

  • 36. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
    Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
    Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy.
    Gattoni-Celli S; Cole DJ
    Semin Oncol; 1996 Dec; 23(6):754-8. PubMed ID: 8970598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune selection after antigen-specific immunotherapy of melanoma.
    Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
    Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
    Voelkl S; Moore TV; Rehli M; Nishimura MI; Mackensen A; Fischer K
    Cancer Immunol Immunother; 2009 May; 58(5):709-18. PubMed ID: 18836718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
    Valmori D; Lévy F; Miconnet I; Zajac P; Spagnoli GC; Rimoldi D; Liénard D; Cerundolo V; Cerottini JC; Romero P
    J Immunol; 2000 Jan; 164(2):1125-31. PubMed ID: 10623865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.